Recruiting

Neuromodulation & Exercise

Sponsor:

University of British Columbia

Code:

NCT04726059

Conditions

Spinal Cord Injuries

Neurogenic Bladder

Neurogenic Bowel

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Transcutaneous Spinal Cord Stimulation

SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation

Activity-Based Therapy

Study Details

Brief summary:

Spinal cord injury (SCI) disrupts many aspects of life, including the loss of volitional movement and involuntary control of bodily functions; both crucial functional recovery priorities for this population. Mobility impairments and secondary complications limit an individual's ability to exercise, a behavior known to have wide-ranging functional and health benefits. This trial will investigate whether activity-based therapy (ABT), using body-weight-supported treadmill training (BWSTT), can change the strength of signals from the brain that control volitional movement, leading to improvements in seated balance as well as other important involuntary bodily (i.e. cardiovascular, urinary tract, bowel and sexual) functions. The investigators aim to determine whether these improvements can be augmented with the addition of non-invasive transcutaneous spinal cord stimulation (TSCS). This therapy has been shown to re-awaken dormant spinal circuits. In this randomized controlled trial, TSCS with ABT, using BWSTT (three sessions/week for twelve weeks), will be compared to ABT+SHAM in individuals with chronic motor-complete spinal cord injury (SCI). Those in the ABT+SHAM group will be given the option to complete an ABT+TSCS open-label follow-up. Before and after training, the following outcomes will be assessed by validated methods: corticospinal excitability, motor function, and seated balance (Hypothesis 1 - Motor Function); severity and frequency of blood pressure instability, urinary tract, bowel, and sexual dysfunctions (Hypothesis 2 - Autonomic Functions); and general health (Hypothesis 3 - Quality of Life). This collaborative project is between consumers with SCI and clinicians/scientists with expertise in SCI care (kinesiologists, physiotherapists, physiatrists, sexual health clinicians). Compared to ABT alone, the investigators anticipate that ABT+TSCS will result in superior improvements in motor and autonomic functions in individuals with SCI.

Conditions

Spinal Cord Injuries

Neurogenic Bladder

Neurogenic Bowel

Study ID

NCT04726059

Start date

Jul 22, 2022

Status verified date

Apr, 2024

Completion date

Dec, 2024

Anticipated

Primary completion date

Dec, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

INCLUSION CRITERIA

A participant must meet all of the following criteria in order to be eligible for inclusion:

  • Resident of British Columbia, Canada with active provincial medical services plan
  • Male or female, 18-60 years of age
  • Chronic traumatic SCI (non-progressive, with complete motor paralysis) at or above the T6 spinal segment
  • At least 1-year post injury, at least 6 months from any spinal surgery
  • American Spinal Injury Association Impairment Scale (AIS) A, B
  • Able to tolerate an upright posture for 30 minutes (with or without breaks)
  • Willing and able to comply with all clinic visits and study-related procedures
  • Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator)
  • No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or active infection that may interfere with testing activities
  • Stable management of spinal cord related clinical issues (i.e., spasticity management)
  • Women of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:

1. Women of childbearing potential must have a confirmed negative pregnancy test prior to the baseline visit. During the trial, all women of childbearing potential will undergo urine pregnancy tests at their monthly clinic visits as outlined in the schedule of events
2. Women of childbearing potential must agree to use adequate contraception during the period of the trial and for at least 28 days after completion of treatment. Effective contraception includes abstinence
  • Sexually active males with female partners of childbearing potential must agree to use effective contraception during the period of the trial and for at least 28 days after completion of treatment
  • Medication dosage must be stable for period of 4 weeks prior to participation
  • Must provide informed consent

EXCLUSION CRITERIA

A participant who meets any of the following criteria will be ineligible to participate:

  • Ventilator dependent
  • Clinically significant, unmanaged, depression (PHQ-9 above 15) or ongoing drug abuse
  • Use of any medication or treatment that in the opinion of the investigator indicates that it is not in the best interest of the participant to participate in this study
  • Intrathecal baclofen pump
  • Oral baclofen dose or other anti-spasticity medications greater than 30mg per day
  • Cardiovascular, respiratory, bladder, or renal disease unrelated to SCI or presence of hydronephrosis or presence of obstructive renal stones
  • Presence of severe acute medical issue that in the investigator's judgement would adversely affect the participant's participation in the study. Examples include, but are not limited to acute urinary tract infections, active heterotopic ossification, newly changed antidepressant medications \[tricyclics\], debilitating muscle pain, pressure sores, or unstable diabetes
  • Any implanted metal (other than dental implants) in the skull or presence of pacemakers, stimulators, or medication pumps in the trunk
  • History of osteoporosis, low bone mineral density, or fragility fractures in the lower limbs
  • History of seizures/epilepsy or recurring headaches
  • Participant has swollen, infected, and inflamed areas or open wounds on the area of stimulation
  • Severe anemia (Hgb<8 g/dl) or hypovolemia as measured by hematocrit via blood test in the last six months
  • Participant is a member of the investigational team or his /her immediate family
  • Participant has undergone electrode implantation surgery

Study Design

Enrollment

12 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

sham comparator: ABT+SHAM

The SHAM is low-intensity, ineffective stimulation delivered at the same anatomical location as TSCS.

experimental: ABT+TSCS

Therapeutic TSCS will be delivered during ABT using an isolated bipolar constant current stimulator. Continuous TSCS applied over the T11-T12 spinous processes at 5-40 Hz has been shown to induce stepping movements in participants with their legs in a gravity-independent position.

Interventions

Transcutaneous Spinal Cord Stimulation

Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.

SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation

Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.

Activity-Based Therapy

Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.

For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics.

Primary outcome measure

  • Change in attempted voluntary motor activation (supine) [ Time Frame: Weeks 2 and 14 ]
  • Change in attempted voluntary motor activation (walking) [ Time Frame: Weeks 2 and 14 ]
  • Change in lower limb proprioceptive sense [ Time Frame: Weeks 2 and 14 ]
  • Change in blood pressure regulation [ Time Frame: Weeks 2 and 14 ]

Central Contacts and Locations

Central contacts

Locations

Blusson Spinal Cord Centre

Recruiting

Vancouver, British Columbia, Canada, V5Z 1M9

Contacts

Principal Investigator:

Andrei Krassioukov, MD,PhD,FRCPC

More Information

Sponsor

University of British Columbia

Last update posted

Apr 30, 2024

Last verified

Apr, 2024

Keywords

  • Activity-based Therapy
  • Spinal Cord Stimulation
  • Transcutaneous Spinal Cord Stimulation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2024-04-30.